

WELLNEX

ASX/AIM Announcement

22 September 2025

Wellnex Life Limited (ASX/AIM:WNX)

Company Update

Wellnex Life Limited (“**Wellnex**” or the “**Company**”) (ASX:WNX AIM:WNX), an innovative consumer healthcare business with a track record for developing, licensing, and marketing products and brands to customers in the growing healthcare market segment, is pleased to provide the following company update.

Wellnex, through its wholly owned subsidiary BSPS Aust Pty Ltd, has received the opening order from its global partner Haleon plc (“Haleon”) for its TGA registered Liquid Paracetamol and Ibuprofen softgel for the United Arab Emirates (UAE). The UAE order opens a fourth national market (after Australia, New Zealand and United Kingdom) in the Haleon global network that will be supported by Wellnex Life and brings an additional product line to our relationship with Haleon in addition to the already launched Liquid Paracetamol softgel.

Whilst the terms of supply, via the Group’s manufacturing partner to Haleon remain confidential, the new agreement for the UAE will generate additional revenue for the Company in the current financial year supporting our market forecasts for the year. The launch of this second product validates Wellnex Life’s strategic focus on developing innovative consumer healthcare products for its own brands and global supply partnerships.

Wellnex Life since 1 July 2025 has currently received confirmed purchase orders from various contract manufacturing customers of c. \$4.6 million. These orders are all expected to be invoiced by no later than the end of December 2025. These confirmed purchase orders are in addition to the contract manufacturing orders of c. \$.800K already invoiced this financial year (total: c. \$5.4million) and revenues from the Company’s other business operations.

Zack Bozinovski, Wellnex Life CEO, said: “We are again excited to see our innovative TGA approved products being launched internationally with such a valued global partner as Haleon. The launch of Liquid Paracetamol and Ibuprofen softgel into the UAE builds on the existing supply agreement for the Liquid Paracetamol softgel which has been supplied into the Australian, New Zealand and United Kingdom markets. We look forward to continuing to partner with global leaders such as Haleon on significant global distribution opportunities for our products into the future.”

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

Zack Bozinovski
Chief Executive Officer
P: +61 3 8399 9419
E: zack.b@wellnexlife.com.au

Reach Markets

T: 1300 805 795
E: IR@reachmarkets.com.au

For personal use only

WELLNEX

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson

Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)

Sebastian Wykeham

swykeham@oranacorp.com

S.P. Angel Corporate Finance LLP (Joint Broker)

Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

About Wellnex Life

Wellnex Life Limited (ASX/AIM:WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing on ASX in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the Company's registered products a distribution channel with a steadily increasing global geographic footprint.

In December 2023, Wellnex Life acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

To learn more, please visit: www.Wellnex.Lifelife.com.au/

For personal use only